Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004

2005 ◽  
Vol 11 (4) ◽  
Author(s):  
Mark J Belsey ◽  
Alex K Pavlou
Keyword(s):  
Drug Discovery ◽  
Early Stage ◽  
Target Identification ◽  
New Wave ◽  
Fully Integrated ◽  
Drug Discovery And Development ◽  
The Past ◽  
Initial Stage ◽  
Increasing Demand

As part of Datamonitor's alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and development collaborations between October 2002 and September 2004, which included 524 early-stage deals. Deal analysis shows that the leading pharma and biotech companies (fully integrated players) are the principal collaboration seekers, and that target and product innovation is driving the new wave of 21st century deals. These deals cover all phases of early-stage drug development, with lead product/target identification/validation accounting for the greatest proportion of collaborations. This represents a shift away from initial-stage collaborations, which are primarily focused on technologies such as genomics, as a result of the lack of tangible results that such technologies have delivered in the past. Following the continuously increasing demand for late-stage high-value products, the aim of the money and time invested in these early-stage collaborations is to reverse the pipeline productivity crisis currently affecting the industry's leaders over the mid to long term.

scholarly journals Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report)

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Paul Erhardt ◽  
Kenneth Bachmann ◽  
Donald Birkett ◽  
Michael Boberg ◽  
Nicholas Bodor ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Small Molecule ◽  
Chemical Structure ◽  
Early Stage ◽  
Xenobiotic Metabolism ◽  
Drug Discovery And Development ◽  
Small Molecule Drug ◽  
Technical Report ◽  
Wide Range ◽  
Draft Version

Abstract This project originated more than 15 years ago with the intent to produce a glossary of drug metabolism terms having definitions especially applicable for use by practicing medicinal chemists. A first-draft version underwent extensive beta-testing that, fortuitously, engaged international audiences in a wide range of disciplines involved in drug discovery and development. It became clear that the inclusion of information to enhance discussions among this mix of participants would be even more valuable. The present version retains a chemical structure theme while expanding tutorial comments that aim to bridge the various perspectives that may arise during interdisciplinary communications about a given term. This glossary is intended to be educational for early stage researchers, as well as useful for investigators at various levels who participate on today’s highly multidisciplinary, collaborative small molecule drug discovery teams.

A Role for Virtual Biotechnology Companies in Drug Discovery and Development?

2013 ◽  
Vol 19 (3) ◽  
Author(s):  
Dianne Nicol ◽  
Johnathon Liddicoat ◽  
Christine Critchley
Keyword(s):  
Drug Discovery ◽  
Business Model ◽  
Early Stage ◽  
Policy Implications ◽  
Pharmaceutical Companies ◽  
Virtual Model ◽  
Journal Articles ◽  
Drug Discovery And Development ◽  
Biotechnology Companies ◽  
Novel Method

The orthodox business model of many drug discovery and development companies centres on adding value to early-stage discoveries prior to engaging with large pharmaceutical companies to bring products to market. Anecdotal observations suggest some companies are moving to a ‘virtual’ business model - instead of employing in-house scientists, a skeletal management team runs the company and out-sources all research and development. This article presents a novel method to determine whether companies are virtual, based on author bylines in peer-reviewed journal articles. Applying this method to Australian companies in this sector, the size of the cohort identified as virtual was much larger than anticipated, around 52%. The accuracy of this method has been verified statistically using interview data. This article discusses the value and limitations of this method, positing that it can be used to analyse industry and policy implications that may result from widespread adoption of the virtual model

scholarly journals Transition in successors’ behavior and mindset while managing long-lived small and medium-sized manufacturing enterprises: a qualitative study

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 285
Author(s):  
Hiroo Suzuki ◽  
Yasunobu Kino
Keyword(s):  
Early Stage ◽  
Manufacturing Companies ◽  
Structured Interviews ◽  
Manufacturing Enterprises ◽  
Double Loop Learning ◽  
Initial Stage ◽  
Core Category ◽  
Stable Employment

Background: There have been many studies conducted on succession, which can be considered as the most important issue in family businesses. However, most of these previous studies have focused only on the early stage of succession, uncovering the role of the predecessor and the successor. Only a few studies have made efforts to examine the total lifecycle of succession. The purpose of this study is to explore the process of the transition in successors' behavior and mindset while managing long-lived small and medium-sized manufacturing enterprises throughout the lifecycle of succession. Methods: Semi-structured interviews were conducted with six successors of small and medium-sized manufacturing companies who are more than half a century old. Their answers were analyzed using the Modified-GTA method to construct a hypothetical model. Results: In total, 46 concepts, four categories, 17 subcategories, and one core category were generated. An analysis result diagram using all concepts and categories was formed. From the observation of this diagram, the successors gained confidence in management through the dilemma between autonomy and constraint in the early stage of succession, which was found in previous research. Following the initial stage, the successors responded to the crisis caused by market constraints and created autonomous strategies in their businesses. Conclusions: By experiencing repetitive crises, the successors tend to acquire new perspectives toward the naturally occurring crises. This change of premise by the successors is considered as the process of double-loop learning. Relationships inside and outside the company influence the generation of this viewpoint. From a long-term perspective, a sense of unity with employees, stable employment, and the pursuit of enjoyment constitute the successors' own values in this model.

The importance of synthetic chemistry in the pharmaceutical industry

Science ◽  
2019 ◽  
Vol 363 (6424) ◽  
pp. eaat0805 ◽  
Author(s):  
Kevin R. Campos ◽  
Paul J. Coleman ◽  
Juan C. Alvarez ◽  
Spencer D. Dreher ◽  
Robert M. Garbaccio ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Synthetic Methods ◽  
Past Century ◽  
Synthetic Chemistry ◽  
Drug Discovery And Development ◽  
The Past ◽  
New Concepts ◽  
The Face ◽  
Chemical Matter

Innovations in synthetic chemistry have enabled the discovery of many breakthrough therapies that have improved human health over the past century. In the face of increasing challenges in the pharmaceutical sector, continued innovation in chemistry is required to drive the discovery of the next wave of medicines. Novel synthetic methods not only unlock access to previously unattainable chemical matter, but also inspire new concepts as to how we design and build chemical matter. We identify some of the most important recent advances in synthetic chemistry as well as opportunities at the interface with partner disciplines that are poised to transform the practice of drug discovery and development.

Digital Microscopy Imaging in Drug Discovery and Development

2001 ◽  
Vol 7 (S2) ◽  
pp. 622-623
Author(s):  
Xiaoyou Ying ◽  
Jean Sprinkle Cavallo ◽  
Bruce McCullough
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
Biological Research ◽  
Digital Microscopy ◽  
Microscopy Imaging ◽  
Bioimage Informatics ◽  
Drug Discovery And Development ◽  
Subcellular Organelles ◽  
The Past ◽  
Almost All

Digital microscopy, the integration of digital and microscopy technologies, was initiated for quantitative microscopic image analysis, but it is now for almost all microscopy applications. During the past decade, with the advance of digital technologies, digital microscopy imaging is becoming an indispensable technology in drug discovery.We started establishing state-of-the-art digital microscopy imaging for drug discovery with the investigation of bioimaging applications at our US research site. Our results shown that all the top 5 bioimaging needs require computer-aided microscopy. Based on this investigation and our review of the microscopy imaging applications in the pharmaceutical industry, we determined four directions for microscopy in drug discovery: multidimensional/multimodal microscopy, digitalization, automation, and bioimage informatics.Multidimensional/multimodal microscopy imaging is required by the nature of biological research, which is fundamental in drug discovery. From genomic imaging to pathology observation, we require biological details and compound activities at the levels from subcellular organelles to organ tissues, from cellular signaling to anatomical locations of compounds.

scholarly journals Singapore's biomedical science sector development strategy: Is it sustainable?

10.5912/jcb93 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
Lisa P L Lim ◽  
Michael J Gregory
Keyword(s):  
Development Strategy ◽  
Early Stage ◽  
Biomedical Science ◽  
Small Country ◽  
Development Models ◽  
The Past ◽  
Science Area ◽  
The Uk ◽  
Economic Size

This paper outlines the strategic efforts undertaken by Singapore to establish its national capability in the biomedical science sector, reviews the commercial base as a result of these efforts and compares Singapore's approach with the UK and US development models, discusses the challenges that Singapore faces and raises some questions on the long-term sustainability of the sector.Although Singapore is a small country in terms of geographical size, its economic size is significant, with gross domestic product (GDP) and GDP per capita of US$112bn and US$25,200 respectively in 2002. For the past 40 years, the country has achieved an average annual GDP growth of 8.4 per cent by focusing on manufacturing and productivity improvements. Biotechnology has been earmarked as the next wave of technology that will sustain the country's economic growth. For almost two decades, Singapore has focused its efforts on building capabilities in the biomedical science area to exploit biotechnology and traditional chemistry-based technologies in drug discovery, development and production. The main principle of Singapore's strategy is to locate a sector targeted for growth and then to focus its efforts on building the key pillars to support the sector; identified in this case to be research, early stage funding and specialised infrastructure.

scholarly journals Transition in successors’ behavior and mindset while managing long-lived small and medium-sized manufacturing enterprises: a qualitative study

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 285
Author(s):  
Hiroo Suzuki ◽  
Yasunobu Kino
Keyword(s):  
Early Stage ◽  
Manufacturing Companies ◽  
Structured Interviews ◽  
Manufacturing Enterprises ◽  
Double Loop Learning ◽  
Initial Stage ◽  
Core Category ◽  
Stable Employment

Background: There have been many studies conducted on succession, which can be considered as the most important issue in family businesses. However, most of these previous studies have focused only on the early stage of succession, uncovering the role of the predecessor and the successor. Only a few studies have made efforts to examine the total lifecycle of succession. The purpose of this study is to explore the process of the transition in successors' behavior and mindset while managing long-lived small and medium-sized manufacturing enterprises throughout the lifecycle of succession. Methods: Semi-structured interviews were conducted with six successors of small and medium-sized manufacturing companies who are more than half a century old. Their answers were analyzed using the Modified-GTA method to construct a hypothetical model. Results: In total, 46 concepts, four categories, 17 subcategories, and one core category were generated. An analysis result diagram using all concepts and categories was formed. From the observation of this diagram, the successors gained confidence in management through the dilemma between autonomy and constraint in the early stage of succession, which was found in previous research. Following the initial stage, the successors responded to the crisis caused by market constraints and created autonomous strategies in their businesses. Conclusions: By experiencing repetitive crises, the successors tend to acquire new perspectives toward the naturally occurring crises. This change of premise by the successors is considered as the process of double-loop learning. Relationships inside and outside the company influence the generation of this viewpoint. From a long-term perspective, a sense of unity with employees, stable employment, and the pursuit of enjoyment constitute the successors' own values in this model.

scholarly journals Best of ASCO 2021: new data from triple-negative breast cancer

2021 ◽  
Author(s):  
Christian Singer
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Target Identification ◽  
Conventional Chemotherapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Tumor Entity ◽  
Cancer Setting

SummaryThis year’s ASCO Annual Meeting has been a showcase for the overwhelming success of novel, targeted therapies, particularly in a tumor entity that has – until recently – been felt to be only treatable with chemotherapy. New data are extremely encouraging, but also highlight the need for target identification beyond the classical clinicopathological factors. Both, the Olympia and the Neotala study have been performed in BRCA-mutated tumors, and their results clearly point to the necessity to offer germline testing to HER2-negative high risk early breast cancer. In addition, GeparNuevo once more highlights the fact that immunotherapy is here to stay, not only in the advanced breast cancer setting, but also in early stage breast cancer. The side effect profile is acceptable, and long-term outcome a real improvement to conventional chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document